Article Versions Notes

Urbanska EM, Grauslund M, Koffeldt PR, Truelsen SLB, Löfgren JO, Costa JC, Melchior LC, Sørensen JB, Santoni-Rugiu E. Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC. International Journal of Molecular Sciences. 2023; 24(17):13077. https://doi.org/10.3390/ijms241713077

Urbanska, Edyta M., Morten Grauslund, Peter R. Koffeldt, Sarah L. B. Truelsen, Johan O. Löfgren, Junia C. Costa, Linea C. Melchior, Jens B. Sørensen, and Eric Santoni-Rugiu. 2023. "Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC" International Journal of Molecular Sciences 24, no. 17: 13077. https://doi.org/10.3390/ijms241713077

Urbanska, E. M., Grauslund, M., Koffeldt, P. R., Truelsen, S. L. B., Löfgren, J. O., Costa, J. C., Melchior, L. C., Sørensen, J. B., & Santoni-Rugiu, E. (2023). Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC. International Journal of Molecular Sciences, 24(17), 13077. https://doi.org/10.3390/ijms241713077